Markus Hinder

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Placebo Controlled

Polycystic Ovary Syndrome

Age Related Macular Degeneration

Top Venues

Diabetes, obesity & metabolism

Clinical pharmacology and therapeutics

The Journal of clinical endocrinology and metabolism

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Nadia Zakaria, Nicolas Guerard, Andres Emanuelli, Pravin Dugel, Jen Watts, Melissa Liew, Margarita Gekkieva, Markus Hinder
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration. Pharmacology research & perspectives 10 (2) (2022)
Daniel James Rader, Eleftheria Maratos-Flier, Amanda Nguyen, Douglas Hom, Michael Ferriere, Yifang Li, Jill Kompa, Miljen Martic, Markus Hinder, Craig T Basson, David Yowe, John L Diener, Allison B Goldfine, null null
LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. The Journal of clinical endocrinology and metabolism (2021)
Susanne Tan, Stanislav Ignatenko, Frank Wagner, Anuja Dokras, Jochen Seufert, Denise Zwanziger, Karin Dunschen, Marjorie Zakaria, Neda Huseinovic, Craig T Basson, Ping Mahling, Dagmar Fuhrer, Markus Hinder
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes, obesity & metabolism 23 (11) (2021)
YanLing He, Jül Schofield, Ping Mahling, Anisha E Mendonza, Markus Hinder
Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial. Clinical pharmacology and therapeutics 108 (5) (2020)